中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (6): 405-408.doi: 10.12144/zgmfskin202206405

• 综述 • 上一篇    下一篇

羟氯喹对系统性红斑狼疮患者血脂和血糖影响的研究进展

周杰,李娇,汝林城,金倩玮,郭芸   

  1. 昆明医科大学第二附属医院皮肤科，昆明，650101
  • 出版日期:2022-06-15 发布日期:2022-04-19
  • 通讯作者: 郭芸，E-mail: gunyun256318@163.com

Update of the effect of hydroxychloroquine on dyslipidemia and blood glucose in systemic Lupus Erythematosus patients

ZHOU Jie, LI Jiao, RU Lincheng, JIN Qianwei, GUO Yun   

  1. Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
  • Online:2022-06-15 Published:2022-04-19
  • Contact: GUO Yun, E-mail: gunyun256318@163.com

PDF (PC)

279

摘要： 系统性红斑狼疮是一种慢性自身免疫性疾病，常累及多个系统，可伴有糖代谢、脂代谢的异常。羟氯喹作为系统性红斑狼疮的基础用药之一，已被发现在治疗本病的同时，还对SLE患者的血糖、血脂代谢有保护作用。本文就羟氯喹治疗对系统性红斑狼疮患者血脂和血糖影响的研究进展进行综述。

关键词: 系统性红斑狼疮, 羟氯喹, 血脂异常, 血糖

Abstract: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease, often involving multiple systems, accompanied by abnormal glucose metabolism and lipid metabolism. Hydroxychloroquine has been found to have a protective effect on blood glucose and blood lipid in SLE patients while treating the disease which as one of the basic drugs for systemic lupus erythematosus. The update of the effect of hydroxychloroquine on dyslipidemia and blood glucose in systemic lupus erythematosus patients is reviewed in this article.

Key words: systemic lupus erythematosus, hydroxychloroquine, dyslipidemia, blood glucose